Proportional hazards modeling of risk of persistent* CMV-HCA positivity after allogeneic HSCT, stratified by stem cell source (PBSC vs BM)
| Characteristic . | Univariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . |
|---|---|---|---|---|
| Donor/recipient CMV serostatus | < .001 | |||
| CMV D-/R- | 1 | — | 1 | — |
| CMV D+/R- | 4.403 (1.101-17.60) | — | 5.259 (1.308-21.15) | .02 |
| CMV D+/R+ | 24.01 (7.284-79.15) | — | 37.60 (11.24-125.7) | < .001 |
| CMV D-/R+ | 38.44 (12.00-123.2) | — | 51.13 (15.70-166.5) | < .001 |
| Recipient race: nonwhite | 3.169 (1.842-5.452) | < .001 | 0.867 (0.463-1.625) | .66 |
| Conditioning | ||||
| Reduced-intensity HLA matching | 0.488 (0.301-0.792) | .004 | 0.404 (0.173-0.944) | .036 |
| Mismatched donor | 2.147 (1.248-3.693) | .006 | 1.915 (0.993-3.691) | .06 |
| Donor relatedness: unrelated donor | 1.504 (0.978-2.314) | .06 | 1.464 (0.863-2.484) | .16 |
| Stem cell source: peripheral blood | 0.515 (0.338-0.785) | .002 | —‡ | — |
| Transplantation period | ||||
| 4/2000-6/2001 | 1 | — | 1 | — |
| 7/2001-6/2002 | 0.619 (0.361-1.064) | .08 | 1.141 (0.536-2.427) | .73 |
| 7/2002-6/2003 | 0.378 (0.203-0.703) | .002 | 0.456 (0.180-1.160) | .10 |
| 7/2003-6/2004 | 0.453 (0.254-0.809) | .007 | 0.867 (0.358-2.099) | .75 |
| Acute GVHD†: grades II-IV | 2.549 (1.654-3.929) | < .001 | 1.871 (1.123-3.117) | .016 |
| GVHD prophylaxis regimen | ||||
| Cyclosporine | 1.553 (0.976-2.471) | .06 | 1 | — |
| Tacrolimus alone | 1.443 (0.940-2.215) | .09 | 0.661 (0.277-1.573) | .35 |
| Sirolimus + tacrolimus | 0.613 (0.474-0.795) | .001 | 0.224 (0.091-0.549) | .001 |
| Prednisone | 1.087 (0.640-1.846) | .76 | 1.160 (0.423-3.180) | .77 |
| Methotrexate | 0.899 (0.586-1.380) | .63 | 1.192 (0.531-2.678) | .67 |
| Mycophenolate mofetil | 1.213 (0.586-2.510) | .60 | 0.943 (0.353-2.521) | .91 |
| T-cell depletion | 2.463 (1.507-4.026) | .001 | 1.440 (0.633-3.275) | .38 |
| Characteristic . | Univariate HR (95% CI) . | P . | Multivariate HR (95% CI) . | P . |
|---|---|---|---|---|
| Donor/recipient CMV serostatus | < .001 | |||
| CMV D-/R- | 1 | — | 1 | — |
| CMV D+/R- | 4.403 (1.101-17.60) | — | 5.259 (1.308-21.15) | .02 |
| CMV D+/R+ | 24.01 (7.284-79.15) | — | 37.60 (11.24-125.7) | < .001 |
| CMV D-/R+ | 38.44 (12.00-123.2) | — | 51.13 (15.70-166.5) | < .001 |
| Recipient race: nonwhite | 3.169 (1.842-5.452) | < .001 | 0.867 (0.463-1.625) | .66 |
| Conditioning | ||||
| Reduced-intensity HLA matching | 0.488 (0.301-0.792) | .004 | 0.404 (0.173-0.944) | .036 |
| Mismatched donor | 2.147 (1.248-3.693) | .006 | 1.915 (0.993-3.691) | .06 |
| Donor relatedness: unrelated donor | 1.504 (0.978-2.314) | .06 | 1.464 (0.863-2.484) | .16 |
| Stem cell source: peripheral blood | 0.515 (0.338-0.785) | .002 | —‡ | — |
| Transplantation period | ||||
| 4/2000-6/2001 | 1 | — | 1 | — |
| 7/2001-6/2002 | 0.619 (0.361-1.064) | .08 | 1.141 (0.536-2.427) | .73 |
| 7/2002-6/2003 | 0.378 (0.203-0.703) | .002 | 0.456 (0.180-1.160) | .10 |
| 7/2003-6/2004 | 0.453 (0.254-0.809) | .007 | 0.867 (0.358-2.099) | .75 |
| Acute GVHD†: grades II-IV | 2.549 (1.654-3.929) | < .001 | 1.871 (1.123-3.117) | .016 |
| GVHD prophylaxis regimen | ||||
| Cyclosporine | 1.553 (0.976-2.471) | .06 | 1 | — |
| Tacrolimus alone | 1.443 (0.940-2.215) | .09 | 0.661 (0.277-1.573) | .35 |
| Sirolimus + tacrolimus | 0.613 (0.474-0.795) | .001 | 0.224 (0.091-0.549) | .001 |
| Prednisone | 1.087 (0.640-1.846) | .76 | 1.160 (0.423-3.180) | .77 |
| Methotrexate | 0.899 (0.586-1.380) | .63 | 1.192 (0.531-2.678) | .67 |
| Mycophenolate mofetil | 1.213 (0.586-2.510) | .60 | 0.943 (0.353-2.521) | .91 |
| T-cell depletion | 2.463 (1.507-4.026) | .001 | 1.440 (0.633-3.275) | .38 |